Business Wire

COP26 Warning: World’s Listed Companies to Cause a Temperature Rise Of 3°C

Share

The Paris Agreement climate targets are increasingly out of reach as the world’s publicly listed companies will cause global temperatures to rise by 3°C, according to the latest MSCI Net-Zero Tracker.

With less than 10% of public companies aligned with a 1.5°C temperature rise threshold, the global carbon budget to limit global warming to 1.5°C will be exhausted by November 2026. This timeframe has moved forward by five months in just 90 days since the launch of the Net-Zero Tracker in July.

Henry Fernandez, Chairman and Chief Executive Officer, MSCI, comments: “The findings of the MSCI Net-Zero Tracker should dramatically increase the world’s sense of urgency to reduce greenhouse gas emissions. As the extreme weather events of 2021 have reminded us, climate change is not a ‘potential’ problem 30 or 40 years down the road. It is a clear and present danger to our way of life right now. What we do over the next half-decade — and especially at COP26 in Glasgow — could make the difference between avoiding or experiencing the worst climate impacts. We urge firm action rather than words at COP26 to divert the world from an imminent crisis and chart a path toward a sustainable future.”

Emissions set to rise by 6.7% in 2021

The rapidly shrinking timeframe is being driven by the significant rise in greenhouse gas emissions from public companies as global economic activity rebounds.

The Net-Zero Tracker, a quarterly gauge of climate change progress across a global universe of 9,300 public companies based on the MSCI All Country World Investable Market Index (ACWI IMI), finds that company emissions are set to rise by 6.7% this year.

No sector or region is safe

The Net-Zero Tracker also finds that less than half of listed companies are aligned with a 2°C temperature rise. No sector or region is aligned with the 2°C target. Even low emitting industries such as health care, information technology and financial services have outliers consuming a disproportionate share of their industry’s remaining budget.

From a regional perspective, although companies in developed economies are projected to become more carbon-efficient this century, every region is still emitting in excess. The problem is most extreme in Emerging Markets (EM) EMEA, where the implied temperature rise of listed companies is 4.8°C, followed by EM Americas and EM Asia, which are set to rise by 3.8°C and 3.4°C, respectively. To address this, companies need to cut their absolute carbon emissions by 10% a year on average. However, from 2016 to 2020, less than a quarter of the world’s publicly listed companies managed this feat.

Major gaps in disclosure of emissions — the laggards revealed

As investors and policymakers seek new levels of transparency on emissions, the latest Net-Zero Tracker shows:

  • Saudi Arabian Oil Company, Gazprom PAO and Coal India Limited are the top three listed companies with the largest carbon footprint
  • Shaanxi Coal Industry Company Ltd is the largest emitter to not disclose any of its greenhouse gas emissions
  • GlaxoSmithKline plc, H&M Hennes & Mauritz and Électricité de France S.A. are listed in the top 10 companies that have published the most thorough emissions-reduction targets
  • Gazprom PAO, A.P. Møller – Mærsk A/S and Toyota Industries Corporation reported additional scopes in the previous quarter and are now reporting all company emissions across most of the relevant categories (i.e., Scope 1, 2 and 3)

Remy Briand, Global Head of ESG and Climate at MSCI, adds: “While it is encouraging that some of the world’s largest listed companies are taking important steps by broadening their emissions reporting and setting decarbonization targets, the Net-Zero Tracker shows that major gaps still remain as many are failing to disclose this crucial information. Climate disclosures are critical for investors to help them assess the carbon intensity of companies, to model climate-related financial risk and the impact on the performance of portfolios, and to allocate capital accordingly. Without accurate disclosures, the chances of companies and investors reaching net-zero is a distant reality. We call on policymakers and financial regulators at COP26 to make climate-related disclosures based on international standards mandatory.”

About MSCI Inc.

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.

Notes to Editors
*Gigaton is equal to a billion tons

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
PR@msci.com
Sam Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura Hudson +44 (0) 207 336 9653

MSCI Global Client Services
EMEA Client Service + 44 20 7618.2222
Americas Client Service +1 888 588 4567 (toll free)
Asia Pacific Client Service + 852 2844 9333

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bentley Education Program Expands to Global Scope25.10.2021 23:01:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, as a commitment to expand access to its professional applications to education, today announced the global expansion of the Bentley Education program – offering seamless access to learning licenses of over 60 popular Bentley applications, at no cost, to all eligible students and educators, from middle schools through higher education levels, via the Bentley Education portal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005717/en/ The Bentley Education program helps students develop digital skills that are critical for a qualified talent pipeline to support infrastructure growth and resilience worldwide. (Photo: Business Wire) Following on the initial May 3, 2021 announcement of the launch of Bentley Education in the pilot countries of Australia, the UK, Singapore, Lithuania, and Ireland, the program is gaining a resounding r

X-Chem Acquires ComInnex25.10.2021 21:00:00 EEST | Press release

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 17:30:00 EEST | Press release

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 15:00:00 EEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea

Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 15:00:00 EEST | Press release

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering

Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 15:00:00 EEST | Press release

Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 14:53:00 EEST | Press release

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom